Schema-Root.org logo

 

  cross-referenced news and research resources about

 Merck

Schema-Root.org logo
images:  google   yahoo YouTube
spacer

updated Thu. October 27, 2016 reload page to refresh

-
Dow Jones component Merck & Company Inc. (new) (MRK) saw its stock move -1.74% to $60.87, representing a per-share move of $1.08, on volume of 9.86 million shares for Wednesday.
Merck & Co., Inc. (NYSE:MRK), with -0.23% losses in previous 5 sessions, is under coverage of 22 analysts who collectively assign a hold rating on stock.
Research Triangle Park, N.C. - Burlington-based LabCorp, Merck and Novartis have released their latest earnings. Here's a recap.

Narrows & Raises Outlook: Along with reporting better-than-expected results, Merck narrowed and raised its outlook for the year.
With some key meds falling short of expectations in the third quarter, Merck's vaccines turned in impressive sales to help carry the drug giant to overall growth.
"In this role, Kelly will help us shape and drive our swine marketing strategies, as well as help lead our efforts to make Merck Animal Health our customers' first call for business solutions - creating value for them well beyond our science and ...
Atilla Cansun, chief marketing officer at Merck consumer Health, based in Darmstadt, Germany, talks to PRWeek about the company's WE100 platform, which is "about the right of everybody to look forward to 100 great years and ask their governments for ...
Shares of health-care companies fell, but not by as much as the broad market, after strong earnings from one drug giant. Shares of Merck rose after it said sales of cancer drugs and other newer products offset declines of the popular anti- inflammatory ...
Merck & Co. Inc. (MRK) reported a profit for the third-quarter that increased about 20 percent, while quarterly worldwide sales grew 5 percent.
Merck reported GAAP EPS of $0.78 and adjusted EPS of $1.07 and beat consensus by $0.08 a share. Generated $10.5 billion sales revenue and topped Street estimates by $0.356 billion.
(RTTNews.com) - Merck & Co Inc. ( MRK ) reported earnings for its third quarter that advanced from last year. The company said its bottom line rose to $2.99 billion, or $1.07 per share.
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we've all come to value and expect, please keep the following criteria ...

On 10/24/2016, Merck & Co., Inc. (nyse:MRK) ended trading lower at $60.75 with -0.74% . The firm exchanged hands at a volume of 9,851,939 whereas, the average volume was 10.19M shares.
Merck & Co. garners two drug approvals in as many days from the U.S. Food and Drug Administration. The company announced the first on Monday, revealing it got the okay for its antibiotic counterpart Zinplava (bezlotoxumab).
Merck & Co. logo Merck & Co. (nyse:MRK) issued its quarterly earnings results on Tuesday. The company reported $1.07 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.99 by $0.08.
Merck and Eli Lilly released their latest earnings reports before opening bell this morning. Merck posted adjusted earnings of $1.07 per share on $10.54 billion in revenue.
But there is a bigger problem affecting Merck, Lilly and health care stocks in general -- presidential politics. Cramer said investors are wondering if there will be more of a push to keep drug prices lower in the next administration.
The sales bump wasn't attributable to price increases on Gardasil alone, Merck said, but rather to typical price increases combined with an increasing shift by patients to the more expensive Gardasil 9, which prevents against nine types of HPV compared ...
Shares of Merck & Co. Inc. MRK, +1.24% were up 3% in premarket trade Tuesday after the company beat third-quarter expectations.
Merck & Co. logo Alps advisors Inc. raised its position in Merck & Co. (nyse:MRK) by 13.1% during the SECond quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC).
The anti-infectives field is heating up--and Merck's the latest Big PhaRMA player to win approval for a new entrant. The New Jersey pharma giant Friday snagged a green light for Zinplava, a med meant to reduce comebacks of Clostridium difficile ...
But two weeks ago at the European Society of Medical Oncology (ESMO) meeting Merck presented data from the Keynote-24 Phase III trial that indicated patients treated with Keytruda had a significant progression free survival benefit of 10.3 months ...
Merck's ($MRK) FDA fast-tracked antiviral letermovir has hit its primary endpoint in a Phase III test as the partners look to capitalize on Chimerix's blowup.
Dow Jones component Merck & Company Inc. (new) (MRK) saw its stock move -1.16% to $61.20, representing a per-share move of $0.72, on volume of 7.39 million shares for Friday.
Dow component Merck and Co Inc. (MRK) reports earnings on Oct. 25th, following an entire quarter of running in place within narrow range boundaries set into place after an early August gap.
Merck & Co.'s (MRK) Animal Health segment operates in more than 140 countries worldwide. Global sales for the segment are expected to rise to $915 million in 3Q16, a 10% rise compared to 3Q15.
Vytorin is a blockbuster drug from Merck's cardiovascular franchise, used to lower LDL cholesterol levels in the blood.
Merck & Co. (MRK) is one of the oldest and largest pharmaceutical companies by revenue. It's set to release its 3Q16 earnings on October 25, 2016.
Merck & Co., Inc. (nyse: MRK) announced it has an upcoming PDUFA date on October 23. The FDA has accepted for review Merck's Biologics License application for Bezlotoxumab, an investigational antitoxin for the prevention of Clostridium difficile (C ...
Merck's strengths such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance outweigh the fact that the company shows ...
Merck KGaA and Pfizer have entered into a collaboration with Debiopharm International to evaluate the potential of combining their drugs to treat lung cancer.
Shares of pharmaceutical giant Merck & Co., Inc. (NYSE:MRK) have been on a roll lately. MRK stock jumped last week and reached its highest levels over the past year.
In biopharmaceuticals, Merck sells Gonal-F for fertility, Erbitux for cancer and in cardio-metabolic it has Concor as a top selling brand.
U.S. District Judge Wendy Beetlestone of the Eastern District of Pennsylvania ruled on Tuesday that former Merck market analyst Joni Westawski's suit fell short because she couldn't prove that she engaged in protected whistleblowing activity under the ...
The National Comprehensive cancer Network (NCCN) has weighed in on the checkpoint inhibitor race to first-line treatment in non-small cell lung cancer (NSCLC).
Merck's ($MRK) FDA fast-tracked antiviral letermovir has hit its primary endpoint in a Phase III test as the partners look to capitalize on Chimerix's blowup.
For Q3CY16, we expect Merck to report revenue growth of 6% YoY and 5% QoQ to Rs2.71bn. PhaRMA sales (78% of revenues) are expected to grow by 17% YoY to Rs2.10bn.
Merck conducts its 3rd Luminary for the first time in Francophone Africa. More than 350 African healthcare providers, policy makers and researchers from more ...
Tecentriq (atezolizumab) was first approved in May for treatment of bladder cancer, an indication not yet targeted by the two PD-1 inhibitors on the market - Merck & Co's Keytruda (pembrolizumab) and Bristol-Myers Squibb's Opdivo (nivolumab). Now, the ...
Merck & Co., Inc.MRK is set to report third-quarter 2016 results on Oct 25, before the market opens. Last quarter, the company delivered a positive earnings surprise of 1.09%.
Merck & Co. logo Tufton capital Management cut its stake in shares of Merck & Co. (nyse:MRK) by 3.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC).
Merck & Co.'s ($MRK) U.S. biosimilars are still in the clinic--but the PhaRMA giant wants to prepare the ground for their arrival.
Merck & Co. MRK, +0.93% said Wednesday morning that its investigational antiviral medicine met its primary endpoint in a phase 3 trial.
Simon Sturge, Chief Operating Officer of Merck's biopharma business, cited increasing demand for the firm's "core portfolio of medicines" as a driver for the investment.
Merck has completed the expansion of its biologics API manufacturing facility in Madrid, Spain increasing production capacity by 50%.


spacer

 


 


 


 


 


schema-root.org

     merck

pharmaceutical industry:
     ariad
     astrazeneca
     baxter
     eli lilly
     glaxosmithkline
     merck
     mylan
     novartis
     pfizer
     products
     research
     takeda
     upjohn
     valeant